Prosecution Insights
Last updated: November 04, 2026
Application No. 18/682,155

FULLY HUMAN SINGLE DOMAIN ANTIBODY-BASED ANTI-SARS-COV-2 BISPECIFIC NEUTRALIZING ANTIBODY AND USE THEREOF

Non-Final OA §103§112
Filed
Feb 08, 2024
Priority
Aug 19, 2021 — CN 202110952739.2 +1 more
Examiner
JOHANSEN, PETER N.
Art Unit
1644
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Biomissile (Anji) Pharmaceuticals Co. Ltd.
OA Round
1 (Non-Final)
60%
Grant Probability
Moderate
1-2
OA Rounds
7m
Est. Remaining
84%
With Interview

Examiner Intelligence

Grants 60% of resolved cases
60%
Career Allowance Rate
137 granted / 229 resolved
At TC average
Strong +25% interview lift
Without
With
+24.7%
Interview Lift
resolved cases with interview
Typical timeline
3y 4m
Avg Prosecution
67 currently pending
Career history
289
Total Applications
across all art units

Statute-Specific Performance

§101
4.0%
-36.0% vs TC avg
§103
39.8%
-0.2% vs TC avg
§102
14.0%
-26.0% vs TC avg
§112
24.8%
-15.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 229 resolved cases

Office Action

§103 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant's reply to the Restriction Requirement, dated September 22, 2026, has been received. By way of this submission, Applicant has elected, without traverse, Group I: claims 1-16, drawn to bispecific antibodies. Claims 1-18 are pending in the application. Claims 17 and 18 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on September 22, 2026. Claims 1-16 are therefore under examination before the Office. Priority The Office acknowledges receipt of the Certified Copies of the Priority Documents with a date of August 19, 2021. However, the documents in question are all in Chinese. Should applicant desire to obtain the benefit of foreign priority under 35 U.S.C. 119(a)-(d) prior to declaration of an interference, a certified English translation of the foreign application must be submitted in reply to this action. 37 CFR 41.154(b) and 41.202(e). Failure to provide a certified translation may result in no benefit being accorded for the non-English application. Any showing of priority that relies on a non-English language application is prima facie insufficient if no certified translation of the application is on file. MPEP 2304.01(c). Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph: Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claim 2 is rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Claim 1 recites a bispecific antibody that binds to SARS-CoV-2, comprising two single domain antibodies sdAb-1 and sdAb-2, wherein the sdAb-1 has an amino acid sequence shown in SEQ ID NO: 1, and the sdAb-2 has an amino acid sequence shown in SEQ ID NO: 2. Claim 2, which depends from claim 1, permits only 90% identity to the above sequences. Claim 2 impermissibly broadens claim 1 by allowing variations in amino acid sequences that are already defined by claim 1. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim 1 is rejected under 35 U.S.C. 103 as being unpatentable over Wu (Cell Host Microbe. 2020 Jun 10;27(6):891-898.e5, cited in IDS). Wu teaches single domain antibodies against SARS-CoV-2, identified as n3113 and n3130 (page 893, right column, first paragraph and Figure 2). Wu further teaches that the small size of these antibodies makes them ideal for use in bispecific antibodies, and such modifications were within the skill of one of ordinary skill (page 896, right column, first paragraph: "Lastly, single-domain antibodies can be used alone or synergistically with other neutralizing antibodies. Their small size makes them ideal building blocks for generation of bispecific or multi-specific antibodies to prevent the appearance of viral escape mutants. They can also be easily engineered to further increase neutralization activity by increasing binding moieties."). Wu further teaches combinations of n3113 and n3130 together to neutralize SARS-CoV-2 (Figure 3B). While Wu does not teach antibodies with the claimed sequences, Applicant's specification at page 16 identifies SEQ ID NOs: 1 and 2 as n3113 and n3130, respectively. As Wu teaches the same antibodies, Wu therefore inherently teaches the sequences of SEQ ID NO: 1 and 2. There is no requirement that a person of ordinary skill in the art would have recognized the inherent disclosure at the relevant time, but only that the subject matter is in fact inherent in the prior art reference. Schering Corp. v. Geneva Pharm. Inc., 339 F.3d 1373, 1377, 67 USPQ2d 1664, 1668 (Fed. Cir. 2003). MPEP 2112(II). While Wu does not teach every aspect of the claims in a single embodiment, it would have been prima facie obvious for a person of ordinary skill in the art as of the effective filing date to follow the teachings of Wu to arrive at the claimed invention. Wu teaches the single-domain antibodies of the claim and suggests that they may be combined into a bispecific antibody, and that such engineering is within the grasp of the ordinary artisan. One of ordinary skill could follow the teachings of Wu to arrive at the claimed invention, with each component of the combination performing its known, usual function, and the combination would have yielded nothing more than predictable results. Claims 1-2, 5-6, 13-14, and 16 are rejected under 35 U.S.C. 103 as being unpatentable over Sevy (WO2023205239A2). Sevy teaches antibodies n3113 and n3130, with sequences identical to those of Applicant's SEQ ID NOs: 1 and 2 (Table 17). Sevy further teaches that such antibodies may be single domain antibodies or bispecific antibodies with two single chain fragments joined together by a glycine-serine linker (para. 0089). Sevy further teaches that the antibodies are variable regions of a heavy chain (VHH) (para. 0006), which is pertinent to claim 5. Sevy further teaches that the antibodies are human antibodies (para. 0080), which is pertinent to claim 6. Sevy further teaches plasmids comprising a polynucleotide sequence encoding a heavy chain variable domain of the antibody (para. 0004), which is pertinent to claims 13 and 14. While Sevy does not teach every aspect of the claims in a single embodiment, it would have been prima facie obvious for a person of ordinary skill in the art as of the effective filing date to follow the teachings of Sevy to arrive at the claimed invention. Sevy teaches the single-domain antibodies of the invention, as well as guidance that such antibodies may be made bispecific by combining them with a glycine-serine linker. One of ordinary skill could follow the teachings of Sevy to arrive at the claimed invention, with each component of the combination performing its known, usual function, and the combination would have yielded nothing more than predictable results. Applicant is invited to file a certified translation of the foreign priority document in order to address this issue. Claims 1-16 are rejected under 35 U.S.C. 103 as being unpatentable over Babb (U.S. patent 10,787,501) in view of Wu (Cell Host Microbe. 2020 Jun 10;27(6):891-898.e5, cited in IDS) and Glaven (Biosensors (Basel). 2012 Feb 1;2(1):43-56). Babb teaches bispecific antibodies, comprising two antigen-binding domains that bind to different epitopes of SARS-CoV-2, and may also contain an IgG1 domain (col. 42, lines 27-55). Babb also teaches single domain antibodies (col. 16, lines 8-10). Babb further teaches that the two antibodies may be joined by a linker such as (GGGGS)4 (col. 43, lines 27-30), which is pertinent to claim 4. Babb further teaches that the above antibodies may comprise human IgG1 (col. 41, lines 25-30), which is pertinent to claims 7-9. Babb further teaches conjugates of antibodies and detectable labels, such as fluorescent labels or radiolabels (col. 53, lines 2-16), which is pertinent to claims 10-12. Babb further teaches that nucleic acids encoding the antibody may be introduced into host cells via a vector (col. 13, lines 35-57), which is pertinent to claims 13-15. Babb further teaches pharmaceutical compositions, comprising the above antibody and a pharmaceutically acceptable carrier or excipient (col. 45, lines 44-48), which is pertinent to claim 16. Babb also teaches that the above pharmaceutical composition may be in a suitable dose (para. col. 52, lines 50-62). However, Babb does not teach the claimed sequences. Wu teaches single domain antibodies against SARS-CoV-2, identified as n3113 and n3130 (page 893, right column, first paragraph and Figure 2). Wu further teaches that the small size of these antibodies makes them ideal for use in bispecific antibodies, and such modifications were within the skill of one of ordinary skill (page 896, right column, first paragraph: "Lastly, single-domain antibodies can be used alone or synergistically with other neutralizing antibodies. Their small size makes them ideal building blocks for generation of bispecific or multi-specific antibodies to prevent the appearance of viral escape mutants. They can also be easily engineered to further increase neutralization activity by increasing binding moieties."). Wu further teaches combinations of n3113 and n3130 together to neutralize SARS-CoV-2 (Figure 3B). Glaven teaches a bispecific antibody, comprising two single domain antibodies that bind to different antigens on the same protein, wherein the C-terminus of the first sdAb is linked to the N-terminus of the second sdAb (page 52, last paragraph). It would have been prima facie obvious for a person of ordinary skill in the art as of the effective filing date to combine the teachings of Wu, Babb, and Glaven to arrive at the claimed invention. An ordinary artisan would have been motivated to do so, and have a reasonable expectation of success, since all of Wu, Babb, and Glaven teach bispecific single domain antibodies. Starting from the teachings of Babb, single domain antibodies that bind SARS-CoV-2 were known in the art. Wu teaches two suitable single domain antibodies that could be used in such a construct, as well as a suggestion to combine them together into a bispecific construct. Additional features of how the two antibodies are joined together are taught by Glaven. A person of ordinary skill in the art could apply the SARS-CoV-2 binding domains of Wu to the bispecific construct of Babb, in the arrangement taught by Glaven to arrive at the claimed invention, with each component of the combination performing its known, usual function, and the combination would have yielded nothing more than predictable results. While Wu does not teach antibodies with the claimed sequences, Applicant's specification at page 16 identifies SEQ ID NOs: 1 and 2 as n3113 and n3130, respectively. As Wu teaches the same antibodies, Wu therefore inherently teaches the sequences of SEQ ID NO: 1 and 2. There is no requirement that a person of ordinary skill in the art would have recognized the inherent disclosure at the relevant time, but only that the subject matter is in fact inherent in the prior art reference. Schering Corp. v. Geneva Pharm. Inc., 339 F.3d 1373, 1377, 67 USPQ2d 1664, 1668 (Fed. Cir. 2003). MPEP 2112(II). Conclusion No claim is allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to PETER JOHANSEN whose telephone number is (571)272-0280. The examiner can normally be reached Monday-Friday, 6:00 to 2:00. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Samira Jean-Louis can be reached at (571) 270-3503. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /PETER JOHANSEN/Primary Examiner, Art Unit 1644
Read full office action

Prosecution Timeline

Feb 08, 2024
Application Filed
Oct 21, 2026
Non-Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12780925
PROTEINS BINDING NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGEN
6y 11m to grant Granted Nov 03, 2026
Patent 12710421
NON-INVASIVE ASSAY FOR DIFFERENTIATING BETWEEN BACTERIAL AND VIRAL INFECTIONS
4y 2m to grant Granted Aug 18, 2026
Patent 12636344
PREFERENTIALLY EXPRESSED ANTIGEN IN MELANOMA (PRAME) T CELL RECEPTORS AND METHODS OF USE THEREOF
3y 10m to grant Granted May 26, 2026
Patent 12600765
NOVEL TARGET FOR ANTI-CANCER AND IMMUNE-ENHANCING
5y 0m to grant Granted Apr 14, 2026
Patent 12601748
PROSPECTIVE MARKERS IN TRAUMATIC BRAIN INJURY (TBI)
4y 8m to grant Granted Apr 14, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
60%
Grant Probability
84%
With Interview (+24.7%)
3y 4m (~7m remaining)
Median Time to Grant
Low
PTA Risk
Based on 229 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month